NCT00567359View on ClinicalTrials.gov

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2017

Study Completion Date

December 31, 2017

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Erlotinib

Oral drug taken daily around the same time. Starting dose is 150mg once daily.

Trial Locations (8)

10021

Memorial Sloan Kettering Cancer Center, New York

44195

Taussig Cancer Center, Cleveland

63110

Washington University School of Medicine, St Louis

94305

Stanford University, Stanford

02114

Massachusetts General Hosptial, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

01960

North Shore Medical Center, Peabody

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT00567359 - Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR | Biotech Hunter | Biotech Hunter